Welcome to the Wyoming Chapter of the American College of Cardiology
Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.
For more information and to register, please visit: ACC Rockies Chapter Meeting 2026
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- HF Commentaries: Adipokine Hypothesis For CpcPH-HFpEF; AI in EHR AnalysisTreating elevated pulmonary vascular resistance (PVR) alone in patients with heart failure with preserved ejection fraction (HFpEF) and combined postcapillary and precapillary pulmonary hypertension (CpcPH-HFpEF) may target the wrong mechanism and only address downstream consequences...
- Higher Coronary Blood Flow in Women May Help Explain Delayed CAD PresentationWomen in the CENTURY trial had higher coronary blood flow (CBF) than men while having a comparable burden of cardiovascular risk factors, similar treatment response and half the coronary events, offering a potential physiological explanation for the delayed clinical manifestation of coronary artery disease (CAD) in women...
- CREST-2, CREST-H: Revascularization Does Not Improve Cognition in Asymptomatic Carotid StenosisFor patients with severe asymptomatic carotid artery stenosis, adding revascularization with either carotid artery stenting (CAS) or carotid endarterectomy (CEA) to intensive medical management (IMM) did not improve cognition compared with IMM alone...
- ATTR-CM: Concomitant Therapy and Vutrisiran Treatment Effect; New Disease Progression FrameworkConcomitant use of tafamidis or heart failure (HF) therapies did not modify the treatment benefit of vutrisiran on all-cause mortality and recurrent cardiovascular events, according to a HELIOS-B analysis recently published in JACC.
- Eagle’s Eye View: Can Extreme Heat Impact Blood Pressure?In this week’s View, Dr. Eagle looks at a recent JACC: Advances Viewpoint that examines the challenges associated with implementing revisions to the definition of first medical contact (FMC) introduced in the 2025 ACC/AHA ACS Guideline and its implications for NCDR data collection.